Tech Company Financing Transactions
Geneoscopy Funding Round
On 1/8/2025, Geneoscopy announced $105 million in Series C funding from Granger Management, LabCorp and Lightchain.
Transaction Overview
Company Name
Announced On
1/8/2025
Transaction Type
Venture Equity
Amount
$105,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to continue investing in its innovative pipeline of diagnostic tests for inflammatory bowel disease, addressing a critical unmet medical need.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
20 S Sarah St.
St. Louis, MO 63108
USA
St. Louis, MO 63108
USA
Phone
Undisclosed
Website
Email Address
Overview
Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient's least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasive colonoscopy. Geneoscopy is changing that.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andrew Barnell
Browse more venture capital transactions:
Prev: 1/8/2025: Mili Software venture capital transaction
Next: 1/8/2025: VitVio venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. VC transactions on this site are derived from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs